Clozapine induced megacolon with stercoral colitis successfully managed with conservative treatment

Abstract Clozapine is a second-generation antipsychotic with proven efficacy in treatment-resistant schizophrenia patients; however, it requires careful monitoring due to its serious side effects. While its most well-known side effect is agranulocytosis, gastrointestinal hypomotility is a less recognized but potentially fatal complication. This article presents a case of a 37-year-old male patient weighing 73 kg who had been taking 300 mg of clozapine daily for two years and developed megacolon and stercoral colitis as a result of clozapine-induced gastrointestinal hypomotility. The patient presented to the emergency department after three months of constipation complaints; abdominal computed tomography revealed marked colonic dilatation and fecal impaction. Clozapine treatment was discontinued, conservative treatment was administered, and clinical improvement was achieved. The patient was discharged completely recovered without the need for surgical intervention. This case highlights the rare but serious gastrointestinal side effects of clozapine and demonstrates that early diagnosis and appropriate treatment can prevent mortality. It is clinically critical to inquire about constipation symptoms in patients using clozapine and to perform early evaluation for megacolon.

Authors

Institutions

Publication Details

Journal
Discover Medicine
Published
2026-06-26
DOI
https://doi.org/10.1007/s44337-026-00622-8
Primary Topic
Gastrointestinal motility and disorders
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Clozapine induced megacolon with stercoral colitis successfully managed with conservative treatment

Mustafa Burak Sayhan, Eray Çeliktürk, Aykut Yucal, Eren Şahin
Discover Medicine
Gastrointestinal motility and disorders
article

Clozapine induced megacolon with stercoral colitis successfully managed with conservative treatment

Mustafa Burak Sayhan, Eray Çeliktürk, Aykut Yucal, Eren Şahin
article en

Abstract

Abstract Clozapine is a second-generation antipsychotic with proven efficacy in treatment-resistant schizophrenia patients; however, it requires careful monitoring due to its serious side effects. While its most well-known side effect is agranulocytosis, gastrointestinal hypomotility is a less recognized but potentially fatal complication. This article presents a case of a 37-year-old male patient weighing 73 kg who had been taking 300 mg of clozapine daily for two years and developed megacolon and stercoral colitis as a result of clozapine-induced gastrointestinal hypomotility. The patient presented to the emergency department after three months of constipation complaints; abdominal computed tomography revealed marked colonic dilatation and fecal impaction. Clozapine treatment was discontinued, conservative treatment was administered, and clinical improvement was achieved. The patient was discharged completely recovered without the need for surgical intervention. This case highlights the rare but serious gastrointestinal side effects of clozapine and demonstrates that early diagnosis and appropriate treatment can prevent mortality. It is clinically critical to inquire about constipation symptoms in patients using clozapine and to perform early evaluation for megacolon.

Discover MedicineVol. 3(1)
Trakya University (TR)
Good health and well-being
Openalex Percentile: Top 5%
Gastrointestinal motility and disorders
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.